Ghana’s Ministry of Health recently launched the Nationwide Mosquito Control Programme (NAMCOP) in conjunction with the waste management company Zoomlion Ghana Limited, the Ghanaian Chronicle/allAfrica.com reports.
Private Sector Involvement
Also In Global Health News: Venezuela Voids Pharma Patents; Namibia Sanitation; Mapping Disease With Satellites; Zimbabwe Health Funding
Venezuela To Void Some Pharmaceutical Patents Commerce Minister Eduardo Saman on Saturday said Venezuela plans to void some pharmaceutical patents and allow domestic manufacturers to produce licensed medicines, the AP/Buffalo News reports. “Saman said the measure is aimed at making the interests of powerful drug companies secondary to the needs…
Innovative Health Financing Can Benefit Global Health, Pharma: “The launch of pneumococcal vaccination in Nicaragua under AMC [advance market commitment] has shown that innovative approaches to health financing can benefit both global health and pharmaceutical companies,” according toÂ a Lancet Infectious Diseases editorial that describes how the roll-out of GAVI initiative…
“A rise in global funding for research into neglected diseases needs to be matched by a continued focus on delivering practical new ways to curb sickness in the developing world,” according to the third annual report by the Global Funding of Innovation for Neglected Diseases (G-FINDER) released on Wednesday, Reuters reports.
Factors Contributing to HealthÂ Of Women Worldwide: The Kaiser Family Foundation features a narrated slide tutorial by epidemiologist Laurel Spielberg on the health issues facing women around the world. The tutorial touches on issues such as economic status and biological, social, and cultural factors that affect women’s health, as well as…
The U.N. on Friday said Haiti’s cholera outbreak appears to be waning overall, but high death rates from the virus in rural regions of the country remain a concern, the Associated Press reports. According to figures released by the Haitian government, 231,070 cholera cases and 4,549 deaths from the disease have been reported since the outbreak first emerged in October.
President’s Bioethics Commission Names International Panel To Review Whether U.S. Rules Protect Clinical Trial Participants In U.S., Abroad
“Prompted by concerns about an unethical U.S.-sponsored study in the 1940s,” the Presidential Commission for the Study of Bioethical Issues on Tuesday announced the formation of an international panel “that will examine whether current rules adequately protect volunteers in global clinical trials,” Science’s “ScienceInsider” blog reports (Kaiser, 3/1).
A new World Bank plan for Africa aims to expand economies and increase job growth, “while also tackling problems of climate change, disease, food shortages and conflict,” Reuters reports (Wroughton, 3/3). The approach, which was endorsed by the bank’s board of executive directors on Tuesday, “shifts from a more general focus” aimed at improving economic stability and fundamentals to targeting “three key areas such as competitiveness and employment,” Xinhua writes (Mutai, 3/2).
The New York Times reports on how microlending has “prompted political hostility in Bangladesh, India, Nicaragua and other developing countries.” Such negativity “toward microfinance is a sharp reversal from the praise and good will that politicians, social workers and bankers showered on the sector in the last decade.” The article notes “[p]hilanthropists and investors poured billions of dollars into nonprofit and profit-making microlenders, who were considered vital players” in helping to achieve the U.N. Millennium Development Goals (MDGs), including the MDG target to halve extreme poverty by 2015. Such attention “helped the sector reach more than 91 million customers, most of them women, with loans totaling more than $70 billion by the end of 2009,” with half of all borrowers from India and Bangladesh.
India’s patent office “has rejected American drug maker Abbott Laboratories’ patent application for an HIV combination drug, allowing low-cost local drug makers to make and sell their generic versions in India and other countries where the medicine is not patented,” Economic Times reports (1/4). The drug under consideration was Abbott’s “Kaletra, which combines two antivirals, [lopinavir/ritonavir and] is one of the preferred second-line treatments to fight drug-resistant HIV, according to the World Health Organization, which recommends governments include it on their list of essential medicines,” Bloomberg/Businessweek writes (Narayan, 1/4).